Ingo B Runnebaum
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krocker J, Nekljudova V, Loibl S, GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer 2023; 194:113324.
07.09.2023Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
07.09.2023Eur J Cancer 2023; 194:113324
Schmidt Marcus, Nitz Ulrike A, Reimer Toralf, Schmatloch Sabine, Graf Heiko, Just Marianne, Stickeler Elmar, Untch Michael, Runnebaum Ingo B, Belau Antje, Huober Jens, Jackisch Christian, Hofmann Manfred, Krocker Jutta, Nekljudova Valentina, Loibl Sibylle, GBG/AGO-B, NOGGO/WSG study groups
Response
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Response. J Natl Cancer Inst 2014; 106:djt452.
28.02.2014Response
28.02.2014J Natl Cancer Inst 2014; 106:djt452
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike A, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105:1018-26.
16.07.2013Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
16.07.2013J Natl Cancer Inst 2013; 105:1018-26
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Moebus V, Konecny G, Kreienberg R, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Jackisch C, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28:2874-80.
10.06.2010Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
10.06.2010J Clin Oncol 2010; 28:2874-80
Moebus Volker, Konecny Gottfried E, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, von Minckwitz Gunter, Harbeck Nadia, Huober Jens, Schneeweiss Andreas, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Jackisch Christian, Untch Michael